Final phase IIa study results evaluating the CXCR4 antagonist BL-8040 in combination with cytarabine (Ara-C) for the treatment of relapsed/refractory AML patients Meeting Abstract
| Authors: | Borthakur, G.; Tallman, M.; Ofran, Y.; Foran, J.; Uy, G.; DiPersio, J.; Nagler, A.; Rowe, J.; Showel, M.; Altman, J.; Peled, A.; Abraham, M.; Pereg, Y.; Vainstein, A.; Oberkovitz, G.; Lustig, T.; Aharon, A.; Bueso-Ramos, C.; Cortes, J.; Andreeff, M. |
| Abstract Title: | Final phase IIa study results evaluating the CXCR4 antagonist BL-8040 in combination with cytarabine (Ara-C) for the treatment of relapsed/refractory AML patients |
| Meeting Title: | 4th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 16 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2016 Sep 7-10 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2016-09-01 |
| Start Page: | S28 |
| Language: | English |
| ACCESSION: | 117709201 |
| DOI: | 10.1016/j.clml.2016.07.040 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cin20 |
| DOI/URL: | |
| Notes: | Accession Number: 117709201 -- Entry Date: In Process -- Revision Date: 20160829 -- Publication Type: Meeting Abstract: AML-076 -- Supplement Title: Sep2016 Supplement 2 -- Journal Subset: Biomedical; Blind Peer Reviewed; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA -- NLM UID: 101525386. -- Source: cin20 |
